Eric Ashley Adams

Eric Ashley Adams is a declared insider of InMed Pharmaceuticals Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 8 January 2018 to 14 November 2024, the count stands at 15 filings.

The open-market side counts 9 purchases for €103k alongside 2 sales for €1.2M. The net balance comes to €1.1M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2024: 1 purchase and no sales on the market.

A typical purchase (the median) is worth €13k. Across 9 purchases, this insider has always bought alone, with no colleague buying within 30 days.

The latest filing, published on 22 December 2024, reports a transaction in InMed Pharmaceuticals Inc. The most recent open-market purchase was published on 21 February 2024, 976 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.